HIM
CYTK icon

Hutchens Investment Management’s Cytokinetics CYTK Stock Holding History

Hutchens Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$150K Hold
18,500
– – 0.14% 86
2017
Q3 		$268K Buy
+18,500
New +$253K 0.24% 74

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PA
Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Hutchens Investment Management's CYTK Position: Q4 2017 in Review

Hutchens Investment Management held its Cytokinetics (CYTK) position steady in Q4 2017 at 18,500 shares worth $150K. The position accounts for 0.14% of the portfolio, ranked #86.

Hutchens Investment Management first reported a position in CYTK in Q3 2017 and has held it in 2 quarters since. The position peaked at $268K in Q3 2017. 134 funds tracked by Wall St. Rank hold CYTK as of Q4 2017.

  • Hutchens Investment Management held 18,500 shares of Cytokinetics worth $150K as of Q4 2017.
  • Hutchens Investment Management left its Cytokinetics share count unchanged in Q4 2017.
  • Cytokinetics made up 0.14% of Hutchens Investment Management's portfolio in Q4 2017, its #86 holding.
  • Hutchens Investment Management first reported a position in Cytokinetics in Q3 2017 and has held it in 2 quarters since.
  • Hutchens Investment Management's Cytokinetics position peaked at $268K in Q3 2017.
  • 134 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2017.

Based on Hutchens Investment Management's 13F filing for Q4 2017, filed 10 Jan 2018.